<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496677</url>
  </required_header>
  <id_info>
    <org_study_id>1986-028</org_study_id>
    <secondary_id>TR701-109</secondary_id>
    <nct_id>NCT01496677</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects</brief_title>
  <official_title>A Phase 1 Open-Label Study With Oral TR-701 Free Acid to Assess Pharmacokinetics, Safety, and Tolerability in Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trius Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trius Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetic (PK) profile of TR-700 in elderly subjects versus younger
      control subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label Phase 1 study of a single oral tablet of TR-701 FA 200 mg to compare
      the TR-700 PK profile in elderly subjects (age 65 years and older, with at least 5 subjects
      75 years old or older) and younger control subjects (age 18 to 45 years).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2012</start_date>
  <completion_date type="Actual">February 28, 2012</completion_date>
  <primary_completion_date type="Actual">February 28, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare PK profile of TR-700 FA in elderly subjects versus younger control subjects</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Elderly subjects (65 or older)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Younger adults (18-45 years old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 FA 200 mg</intervention_name>
    <description>Single oral tablet of TR-701 FA to elderly subjects</description>
    <arm_group_label>Elderly subjects (65 or older)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 FA 200 mg</intervention_name>
    <description>Single oral tablet of TR-701 FA to younger group (18-45 years old)</description>
    <arm_group_label>Younger adults (18-45 years old)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects in the following groups: An elderly subject at least 65 years
             of age. At least 5 subjects must be at least 75 years of age OR A matched-control
             subject between 18 and 45 years of age, inclusive

          -  BMI ≥18.0 kg/m2 and ≤35.0 kg/m2

        Elderly Group

          -  Medical history, physical examination, and laboratory results consistent with stable
             health (as determined by the Investigator)

        Control Group

          -  Medically stable with no clinically significant abnormalities

        Exclusion Criteria:

          -  Significant, uncontrolled, or life-threatening condition or organ or system condition
             or disease (eg, impaired cognitive status, respiratory insufficiency, advanced
             malnutrition)

          -  Positive hepatitis B surface antigen, hepatitis C virus antibody, or human
             immunodeficiency virus antibody test result

          -  Previous inclusion in a TR-701 FA or TR-701 clinical study

          -  ECG finding of QTc interval &gt;500 msec, or other clinically significant ECG abnormality
             at Screening

          -  Female subjects whom are pregnant, lactating or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe G Prokocimer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Trius Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trius Investigator Site 001</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2011</study_first_submitted>
  <study_first_submitted_qc>December 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2011</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torezolid phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

